Skip to main content

Azitra, Inc.

AZTR
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001701478

No open-market purchases or sales by Azitra, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Azitra, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Azitra, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Azitra, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Salva Francisco D.President and CEO4,086,291Jun 18, 20264
Whitfill TravisChief Operating Officer334,500Apr 22, 20262
Staskey NormChief Financial Officer51,100Apr 22, 20262
Schroer John R.Director–Dec 22, 20251
Ryan BarbaraDirector–Dec 22, 20251
Bayer Aktiengesellschaft10% Owner1,307,401Jul 24, 20230
Bayer Healthcare LLC10% Owner1,307,401Jul 24, 20230
Bayer World Investments B.V.10% Owner1,307,401Jul 24, 20230
Bayer US Holding LP10% Owner1,307,401Jul 24, 20230
McClary AndrewDirector291,911IndirectJun 29, 20230
BIOS Fund I, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund I QP, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund II, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund II QP, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund II NT, LP10% Owner436,173IndirectJun 23, 20230
Cavu Management, LP10% Owner436,173IndirectJun 23, 20230
Cavu Advisors, LLC10% Owner436,173IndirectJun 23, 20230
Bios Equity Partners II, LP10% Owner436,173IndirectJun 23, 20230
Bios Equity Partners, LP10% Owner436,173IndirectJun 23, 20230
Kreis Leslie W.10% Owner436,173IndirectJun 23, 20230
BIOS Azitra Co-Invest I, LP10% Owner436,173IndirectJun 23, 20230
Fletcher Aaron G.L.10% Owner436,173IndirectJun 23, 20230
BIOS Fund III NT, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund III QP, LP10% Owner436,173IndirectJun 23, 20230
BIOS Fund III, LP10% Owner436,173IndirectJun 23, 20230
BIOS Advisors GP, LLC10% Owner436,173IndirectJun 23, 20230
BIOS Capital Management, LP10% Owner436,173IndirectJun 23, 20230
BIOS Equity Partners III, LP10% Owner436,173IndirectJun 23, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 20, 2026 (view filing)Mar 182 daysSalva Francisco D.President and CEOPPurchase+12.2M–––4.06M afterDerivative3 lots
Apr 1, 2024 (view filing)9:51 PM ETMar 293 daysStaskey NormChief Financial OfficerPPurchase+47.6K$0.2108+$10.0K+1,360.0%51.1K after
Feb 15, 2024 (view filing)8:42 PM ETFeb 132 daysWhitfill TravisChief Operating OfficerPPurchase+15.0K$0.30+$4.50K+4.7%334.5K after
Feb 15, 2024 (view filing)8:39 PM ETFeb 132 daysStaskey NormChief Financial OfficerPPurchase+3.30K$0.30+$990+1,650.0%3.50K after
Feb 15, 2024 (view filing)8:38 PM ETFeb 132 daysSalva Francisco D.President and CEOPPurchase+333.3K$0.30+$100.0K+6,666.0%338.3K after
Jun 23, 2023 (view filing)9:38 PM ETJun 212 daysBIOS Fund I, LP and 9 others10% OwnerSSaleConvertible Notes−669.3K––−100.0%0 after3 lotsDuplicate filing
Jun 23, 2023 (view filing)9:38 PM ETJun 212 daysBIOS Fund I, LP and 9 others10% OwnerPPurchase+2.30M$5.00+$3.00MNew position282.2K after6 lotsDuplicate filing
Jun 23, 2023 (view filing)9:37 PM ETJun 212 daysBIOS Azitra Co-Invest I, LP and 7 others10% OwnerSSaleConvertible Notes−669.3K––−100.0%0 after3 lots
Jun 23, 2023 (view filing)9:37 PM ETJun 212 daysBIOS Azitra Co-Invest I, LP and 7 others10% OwnerPPurchase+2.30M$5.00+$3.00MNew position282.2K after6 lots